BioPharma Resources

Drug Trial Radar · NCT04786262

A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes

A Master Protocol to Evaluate the Safety, Tolerability, and Efficacy of Islet Cell Replacement Therapies in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia: A Phase 1/2/3 Study of VX-880 and a Phase 1/2 Study of VX-017

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

57

Planned (sponsor's estimate)

Start

Mar 29, 2021

Primary completion

Dec 31, 2027

Study completion Dec 31, 2031

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Mar 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability and efficacy of VX-880 infusion and VX-017 infusion in participants with type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.

Conditions

  • Diabetes Mellitus, Type 1
  • Impaired Hypoglycemic Awareness
  • Severe Hypoglycemia

Interventions

  • VX-880Biological

    Infused into the hepatic portal vein.

  • VX-017Biological

    Infused into the hepatic portal vein.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)Time frame: From VX-880 infusion to end of study (at least 5 years)
  2. Parts B and C: Proportion of Participants who are Insulin Independent with Absence of Severe Hypoglycemic Events (SHEs)Time frame: 1 year after achieving insulin independence (following VX-880 infusion)
  3. Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)Time frame: From VX-017 infusion to end of study (at least 5 years)

Locations

29 sites in 10 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • UHealth Diabetes Research Institute

    Miami, Florida · Recruiting

  • Northwestern Organ Transplant Center

    Chicago, Illinois · Completed

  • University of Chicago

    Chicago, Illinois · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Completed

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center Montefiore

    Pittsburgh, Pennsylvania · Recruiting

  • Baylor Scott and White Research Institute

    Dallas, Texas · Recruiting

  • VCU Medical Center, Richmond

    Richmond, Virginia · Recruiting

  • University of Wisconsin

    Madison, Wisconsin · Recruiting

  • University of Alberta, Edmonton

    Edmonton, Canada · Recruiting

  • McGill University Health Centre

    Montreal, Canada · Recruiting

  • Toronto General Hospital (TGH)

    Toronto, Canada · Recruiting

  • Vancouver General Hospital

    Vancouver, Canada · Recruiting

  • CHU Lille

    Lille, France · Recruiting

  • Centre de recherche en Biomédecine de Strasbourg

    Strasbourg, France · Recruiting

  • Dresden Center for Islet Transplantation

    Dresden, Germany · Recruiting

  • IRCCS Ospedale San Raffaele

    Milan, Italy · Recruiting

  • Leiden University

    Leiden, Netherlands · Recruiting

  • Oslo University Hospital

    Oslo, Norway · Recruiting

  • King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology

    Riyadh, Saudi Arabia · Recruiting

  • King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology

    Riyadh, Saudi Arabia · Recruiting

  • Hopiteaux Universitaires de Geneve

    Geneva, Switzerland · Completed

  • Royal Infirmary of Edinburgh

    Edinburgh, United Kingdom · Recruiting

  • Cardiovascular, Metabolic Medicine and Sciences, King's College London

    London, United Kingdom · Recruiting

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom · Recruiting

  • Churchill Hospital

    Headington, Oxford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.